A global, retrospective, post-authorization study to characterize real-world effectiveness and safety of dostarlimab in patients with mismatch repair deficient (dMMR) or high microsatellite instability (MSI-H) recurrent or advanced endometrial cancer from racial and ethnic minority groups and in white patients.
